NCT04626700

Brief Summary

This is the study entitled "Comparison for oral negative pressure therapy and CPAP for OSA under sleep endoscopy assistance: A randomized controlled trial". CPAP is first line golden standard treatment for Obstructive sleep apnea (OSA). However, the overall CPAP compliance is poor. Recent study reveals that oral negative pressure therapy improves apnea severity in OSA patients with good compliance. However, no study is designed to compare oral negative pressure therapy and CPAP for OSA patients. In addition, the effect of oral negative pressure therapy for hypopharynx is unclear. Therefore, we will perform druginduced sleep endoscopy to evaluate upper airway obstruction of OSA patients before treatment. OSA patients will be assigned into oral negative pressure group or CPAP group for 2 months. Sleepiness, sleep quality, residual apnea severity and compliance will be evaluated.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Aug 2019

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 14, 2019

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

November 1, 2020

Completed
11 days until next milestone

First Posted

Study publicly available on registry

November 12, 2020

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2022

Completed
Last Updated

November 12, 2020

Status Verified

October 1, 2020

Enrollment Period

2.9 years

First QC Date

November 1, 2020

Last Update Submit

November 6, 2020

Conditions

Outcome Measures

Primary Outcomes (3)

  • The Epworth Sleepiness Scale (ESS)

    lower ESS means better outcome

    Change from Baseline ESS at 1 month

  • The Epworth Sleepiness Scale (ESS)

    lower ESS means better outcome

    Change from Baseline ESS at 2 months

  • apnea-hypopnea index (AHI)

    lower AHI means better outcome

    Change from Baseline AHI at 2 months

Study Arms (2)

iNAP

EXPERIMENTAL
Device: iNAP

CPAP

ACTIVE COMPARATOR
Device: CPAP

Interventions

iNAPDEVICE

iNAP for the treatment of OSA

iNAP
CPAPDEVICE

CPAP for the treatment of OSA

CPAP

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • mild to moderate OSA

You may not qualify if:

  • hypopharynx obstruction
  • ASA classification of physical status)\>3
  • allergy toDexmedetomidine
  • COPD stage IV
  • Asthma with exacerbation
  • severe CHF
  • age \< 18 year-old
  • claustraphobia
  • any reason : can not tolerate CPAP
  • second or third degree AVB

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Division of Thoracic Medicine, Chang Gung Memorial Hospital

Taipei, 105, Taiwan

RECRUITING

Study Officials

  • Tsang-Tang Hsieh, MD

    Institutional Review Board Chang Gung Medical Foundation

    STUDY CHAIR

Central Study Contacts

Tsai-Yu Wang, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 1, 2020

First Posted

November 12, 2020

Study Start

August 14, 2019

Primary Completion

June 30, 2022

Study Completion

June 30, 2022

Last Updated

November 12, 2020

Record last verified: 2020-10

Locations